CL2018000140A1 - Inhibidores del receptor del factor estimulador de colonias 1 (csf-1r) - Google Patents

Inhibidores del receptor del factor estimulador de colonias 1 (csf-1r)

Info

Publication number
CL2018000140A1
CL2018000140A1 CL2018000140A CL2018000140A CL2018000140A1 CL 2018000140 A1 CL2018000140 A1 CL 2018000140A1 CL 2018000140 A CL2018000140 A CL 2018000140A CL 2018000140 A CL2018000140 A CL 2018000140A CL 2018000140 A1 CL2018000140 A1 CL 2018000140A1
Authority
CL
Chile
Prior art keywords
csf
stimulating factor
colony stimulating
receptor inhibitors
inhibitors
Prior art date
Application number
CL2018000140A
Other languages
English (en)
Inventor
John L Kane Jr
Claude Barberis
Mark Czekaj
Paul Erdman
Barret Giese
Michael Kothe
Tieu-Binh Le
Jinyu Liu
Liang Ma
Markus Metz
Vinod Patel
Andrew Scholte
Patrick Shum
Limli Wei
Original Assignee
Genzyme Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Genzyme Corp filed Critical Genzyme Corp
Publication of CL2018000140A1 publication Critical patent/CL2018000140A1/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A61K31/4184—1,3-Diazoles condensed with carbocyclic rings, e.g. benzimidazoles
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/04—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/437—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/06—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D519/00—Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Immunology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Epidemiology (AREA)
  • Transplantation (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Hospice & Palliative Care (AREA)
  • Rheumatology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Psychiatry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Hydrogenated Pyridines (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Pyridine Compounds (AREA)
  • Peptides Or Proteins (AREA)

Abstract

Compuestos de fórmulas y que son útiles como inhibidores del receptor del factor estimulador de colonias 1 (CSF-1R) (“inhibidores de CSF 1R”).
CL2018000140A 2015-07-20 2018-01-17 Inhibidores del receptor del factor estimulador de colonias 1 (csf-1r) CL2018000140A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US201562194619P 2015-07-20 2015-07-20

Publications (1)

Publication Number Publication Date
CL2018000140A1 true CL2018000140A1 (es) 2018-08-17

Family

ID=56551024

Family Applications (1)

Application Number Title Priority Date Filing Date
CL2018000140A CL2018000140A1 (es) 2015-07-20 2018-01-17 Inhibidores del receptor del factor estimulador de colonias 1 (csf-1r)

Country Status (28)

Country Link
US (2) US11274108B2 (es)
EP (1) EP3325471A1 (es)
JP (3) JP6898914B2 (es)
KR (1) KR102665765B1 (es)
CN (1) CN107922396B (es)
AR (1) AR105392A1 (es)
AU (3) AU2016297558B2 (es)
BR (1) BR112018001017B1 (es)
CA (2) CA2993018A1 (es)
CL (1) CL2018000140A1 (es)
CO (1) CO2018001621A2 (es)
CR (1) CR20180109A (es)
DO (1) DOP2018000008A (es)
EC (1) ECSP18012103A (es)
GT (1) GT201800020A (es)
IL (3) IL305843A (es)
MA (1) MA42023B2 (es)
MX (2) MX2018000880A (es)
MY (1) MY186368A (es)
NZ (1) NZ739951A (es)
PE (1) PE20180573A1 (es)
PH (1) PH12018500140A1 (es)
RU (1) RU2748884C2 (es)
SG (1) SG10201912699RA (es)
TN (1) TN2018000020A1 (es)
TW (1) TWI734693B (es)
WO (1) WO2017015267A1 (es)
ZA (1) ZA201800082B (es)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DK2691384T3 (en) 2011-03-28 2017-01-16 Mei Pharma Inc (ALPHA-SUBSTITUTED ARALKYLAMINO AND HETEROARYLALKYLAMINO) PYRIMIDINYL AND 1,3,5-TRIAZINYL BENZIMIDAZOLES, PHARMACEUTICAL COMPOSITIONS CONTAINING THEMSELVES AND THEIR SUBSTANCES CONCERNING THE USE OF THE USE
CA3063976A1 (en) 2017-05-23 2018-11-29 Mei Pharma, Inc. Combination therapy
IL273741B (en) 2017-08-04 2022-09-01 Skyhawk Therapeutics Inc Methods and compositions for fusion modulation
MA49921A (fr) 2017-08-14 2021-05-12 Mei Pharma Inc Polythérapie
CN114007613A (zh) 2019-02-05 2022-02-01 斯基霍克疗法公司 用于调节剪接的方法和组合物
JP2022519323A (ja) 2019-02-06 2022-03-22 スカイホーク・セラピューティクス・インコーポレーテッド スプライシングを調節するための方法および組成物
MX2021011923A (es) * 2019-03-29 2021-11-03 Kowa Co Novedoso derivado de azaindol.
CA3185649A1 (en) 2020-07-20 2022-01-27 Bakary-Barry Toure Indole compounds as androgen receptor modulators
JP2023542041A (ja) * 2020-09-21 2023-10-04 ハチソン メディファルマ リミテッド ヘテロ芳香族化合物及びその使用
EP4267573A1 (en) * 2020-12-23 2023-11-01 Genzyme Corporation Deuterated colony stimulating factor-1 receptor (csf-1r) inhibitors
WO2022140528A1 (en) 2020-12-23 2022-06-30 Genzyme Corporation Deuterated colony stimulating factor-1 receptor (csf-1r) inhibitors
WO2023249989A1 (en) 2022-06-22 2023-12-28 Genzyme Corporation Solid forms of deuterated colony stimulating factor-1 receptor (csf-1r) inhibitors

Family Cites Families (60)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4612323A (en) * 1983-06-27 1986-09-16 Sumitomo Chemical Company, Limited Insecticidal and acaricidal derivatives of 1-benzylbenzimidazole
JPS61151176A (ja) * 1984-12-24 1986-07-09 Sumitomo Chem Co Ltd ベンズイミダゾール誘導体およびそれを有効成分とする殺虫、殺ダニ剤
US5187159A (en) * 1991-10-07 1993-02-16 Merck & Co., Inc. Angiotensin II antagonists incorporating a substituted 1,3-benzodioxole or 1,3-benzodithiole
WO1994000450A1 (en) * 1992-06-25 1994-01-06 Zeneca Limited Chromanderivatives as angiotensin ii antagonists
FR2693197B1 (fr) * 1992-07-03 1994-09-23 Synthelabo Nouveaux dérivés de quinoléine, leur procédé de préparation et leur application thérapeutique.
US6765008B1 (en) * 1992-12-17 2004-07-20 Pfizer Inc Pyrrolopyrimidines as CRF antagonists
ZA939516B (en) 1992-12-22 1994-06-06 Smithkline Beecham Corp Endothelin receptor antagonists
JPH09202774A (ja) * 1996-01-25 1997-08-05 Green Cross Corp:The ２−アリールキノリン類およびその製造方法
JPH101471A (ja) * 1996-06-13 1998-01-06 Green Cross Corp:The Ｎ−［（キノリン−２−イル）フェニル］スルホンアミド類の結晶およびその製造方法
KR20000035869A (ko) * 1996-08-30 2000-06-26 가마쿠라 아키오 근조직 변성의 예방 또는 치료제
KR20010014183A (ko) * 1997-06-27 2001-02-26 Fujisawa Pharmaceutical Co 술폰아미드 화합물 및 그의 의약 용도
EP0994877A1 (en) 1997-07-03 2000-04-26 Du Pont Pharmaceuticals Company Imidazopyrimidines and imidazopyridines for the treatment of neurological disorders
US6130333A (en) * 1998-11-27 2000-10-10 Monsanto Company Bicyclic imidazolyl derivatives as phosphodiesterase inhibitors, pharmaceutical compositions and method of use
US7135495B2 (en) * 2000-03-09 2006-11-14 Ono Pharmaceutical Co., Ltd. Indole derivatives
WO2001066520A1 (fr) * 2000-03-09 2001-09-13 Ono Pharmaceutical Co., Ltd. Derives indole, procede de preparation de ces derives et leur utilisation
PA8535601A1 (es) 2000-12-21 2002-11-28 Pfizer Derivados benzimidazol y piridilimidazol como ligandos para gabaa
US7030150B2 (en) * 2001-05-11 2006-04-18 Trimeris, Inc. Benzimidazole compounds and antiviral uses thereof
CA2483084A1 (en) * 2002-05-02 2003-11-13 Merck & Co., Inc. Tyrosine kinase inhibitors
CA2511806A1 (en) 2003-01-22 2004-08-12 Eli Lilly And Company Indole-derivative modulators of steroid hormone nuclear receptors
DE10342503A1 (de) 2003-09-12 2005-04-14 Merck Patent Gmbh Benzyl-Benzimidazolylderivate
WO2005028434A2 (en) * 2003-09-18 2005-03-31 Conforma Therapeutics Corporation Novel heterocyclic compounds as hsp90-inhibitors
WO2005074603A2 (en) 2004-02-03 2005-08-18 Abbott Laboratories Aminobenzoxazoles as therapeutic agents
EP1755597A2 (en) 2004-06-17 2007-02-28 Plexxikon, Inc. Azaindoles modulating c-kit activity and uses therefor
US7361764B2 (en) 2004-07-27 2008-04-22 Sgx Pharmaceuticals, Inc. Pyrrolo-pyridine kinase modulators
DE602005020957D1 (de) * 2004-09-03 2010-06-10 Yuhan Corp Pyrroloä3,2-cüpyridinderivate und verfahren zu deren herstellung
TWI278682B (en) 2004-11-23 2007-04-11 Ind Tech Res Inst Fiber optic interferometric position sensor and measuring method thereof
BRPI0518794A2 (pt) * 2004-12-01 2008-12-09 Osi Pharm Inc composto, composiÇço, mÉtodo de tratamento de distérbio hiperproliferativo, e, biblioteca combinatorial
FR2883286B1 (fr) * 2005-03-16 2008-10-03 Sanofi Aventis Sa NOUVEAUX DERIVES D'IMIDAZO[1,5-a]PYRIDINES, INHIBITEURS DE FGFs, LEUR PROCEDE DE PREPARATION ET LES COMPOSITIONS PHARMACEUTIQUES LES CONTENANT
JP2008545652A (ja) 2005-05-17 2008-12-18 プレキシコン，インコーポレーテッド ｃ−ｋｉｔおよびｃ−ｆｍｓ活性を調節する化合物およびその用途
MY153898A (en) 2005-06-22 2015-04-15 Plexxikon Inc Compounds and methods for kinase modulation, and indications therefor
EP2251341A1 (en) * 2005-07-14 2010-11-17 Astellas Pharma Inc. Heterocyclic Janus kinase 3 inhibitors
NL2000613C2 (nl) 2006-05-11 2007-11-20 Pfizer Prod Inc Triazoolpyrazinederivaten.
PE20080403A1 (es) 2006-07-14 2008-04-25 Amgen Inc Derivados heterociclicos fusionados y metodos de uso
CN101558070A (zh) 2006-10-23 2009-10-14 Sgx药品公司 三唑并哒嗪蛋白激酶调节剂
WO2008051805A2 (en) 2006-10-23 2008-05-02 Sgx Pharmaceuticals, Inc. Triazolo-pyridazine protein kinase modulators
WO2008064219A1 (en) * 2006-11-22 2008-05-29 Johnson Controls Technology Company Multichannel evaporator with flow mixing manifold
WO2008063888A2 (en) * 2006-11-22 2008-05-29 Plexxikon, Inc. Compounds modulating c-fms and/or c-kit activity and uses therefor
RU2009122670A (ru) 2006-12-21 2011-01-27 Плекссикон, Инк. (Us) Соединения и способы для модуляции киназ и показания к их применению
JP2010524953A (ja) * 2007-04-17 2010-07-22 ブリストル−マイヤーズ スクイブ カンパニー 縮合ヘテロ環１１−β−ヒドロキシステロイドデヒドロゲナーゼＩ型阻害剤
WO2009008992A2 (en) 2007-07-06 2009-01-15 Osi Pharmaceuticals Inc. Combination anti-cancer therapy comprising an inhibitor of both mtorc1 and mt0rc2
US8119658B2 (en) 2007-10-01 2012-02-21 Bristol-Myers Squibb Company Triazolopyridine 11-beta hydroxysteroid dehydrogenase type I inhibitors
AU2008323694A1 (en) * 2007-11-07 2009-05-14 Foldrx Pharmaceuticals, Inc. Modulation of protein trafficking
WO2009143018A2 (en) 2008-05-19 2009-11-26 Plexxikon, Inc. Compounds and methods for kinase modulation, and indications therefor
WO2010124082A1 (en) 2009-04-22 2010-10-28 Janssen Pharmaceutica Nv Azetidinyl diamides as monoacylglycerol lipase inhibitors
ES2715611T3 (es) * 2010-05-17 2019-06-05 Incozen Therapeutics Pvt Ltd Compuestos novedosos de 3H-imidazo[4,5-b]piridina-3,5-disustituida y 3H-[1,2,3]triazolo[4,5-b]piridina 3,5-disustituida como moduladores de proteína cinasas
WO2011156632A2 (en) * 2010-06-09 2011-12-15 Georgetown University Compositions and methods of treatment for tumors in the nervous system
CA2818986A1 (en) * 2010-11-24 2012-05-31 Allergan, Inc. Indole derivatives as modulators of s1p receptors
JP2014505088A (ja) 2011-02-10 2014-02-27 ノバルティス アーゲー Ｃ−ＭＥＴチロシンキナーゼ阻害剤としての［１，２，４］トリアゾロ［４，３−ｂ］ピリダジン化合物
US8748435B2 (en) 2011-04-01 2014-06-10 Novartis Ag Pyrazolo pyrimidine derivatives
WO2012160464A1 (en) 2011-05-26 2012-11-29 Daiichi Sankyo Company, Limited Heterocyclic compounds as protein kinase inhibitors
WO2013012649A1 (en) 2011-07-15 2013-01-24 Glaxosmithkline Llc Azaindole compounds and methods for treating hiv
MX368081B (es) * 2011-10-14 2019-09-19 Ambit Biosciences Corp Compuestos heterociclicos y uso de los mismos como moduladores del receptor de tirosina cinasas tipo iii.
CN104010504B (zh) * 2011-11-03 2016-04-06 默沙东公司 作为mGluR2负变构调节剂的喹啉甲酰胺和喹啉甲腈的衍生物、组合物、及其用途
WO2013116182A1 (en) * 2012-01-31 2013-08-08 Boehringer Ingelheim International Gmbh Heterocyclic compounds as inhibitors of leukotriene production
US9358235B2 (en) * 2012-03-19 2016-06-07 Plexxikon Inc. Kinase modulation, and indications therefor
EP2831073B1 (en) * 2012-03-30 2020-12-09 Rhizen Pharmaceuticals S.A. Novel 3,5-disubstitued-3h-imidazo[4,5-b]pyridine and 3,5- disubstitued -3h-[1,2,3]triazolo[4,5-b]pyridine compounds as modulators of c-met protein kinases
WO2014081820A1 (en) 2012-11-20 2014-05-30 Discoverybiomed, Inc. Small molecule cftr correctors
TWI731317B (zh) 2013-12-10 2021-06-21 美商健臻公司 原肌球蛋白相關之激酶（ｔｒｋ）抑制劑
BR112016015236B1 (pt) * 2013-12-30 2023-11-14 Array Biopharma Inc. Composto, composições farmacêuticas, usos de um composto e método in vitro de inibição da atividade da proteína quinase erk
PT3137470T (pt) 2014-05-01 2021-06-24 Novartis Ag Compostos e composições como agonistas do recetor tipo toll 7

Also Published As

Publication number Publication date
CR20180109A (es) 2018-05-03
MX2018000880A (es) 2018-08-24
KR20180030199A (ko) 2018-03-21
RU2748884C2 (ru) 2021-06-01
AU2021204116B2 (en) 2022-12-01
PH12018500140A1 (en) 2018-07-23
IL305843A (en) 2023-11-01
TWI734693B (zh) 2021-08-01
US20220396588A1 (en) 2022-12-15
JP2024028845A (ja) 2024-03-05
IL256964B (en) 2021-10-31
AU2023201013A1 (en) 2023-03-23
CA3217238A1 (en) 2017-01-26
JP2021107414A (ja) 2021-07-29
KR102665765B1 (ko) 2024-05-10
IL256964A (en) 2018-03-29
AU2016297558A1 (en) 2018-03-08
CN107922396A (zh) 2018-04-17
TW201716393A (zh) 2017-05-16
US20190016707A1 (en) 2019-01-17
CN107922396B (zh) 2022-08-05
WO2017015267A1 (en) 2017-01-26
NZ739951A (en) 2024-02-23
JP7401482B2 (ja) 2023-12-19
JP2018524381A (ja) 2018-08-30
GT201800020A (es) 2019-10-21
TN2018000020A1 (en) 2019-07-08
BR112018001017B1 (pt) 2024-02-15
CA2993018A1 (en) 2017-01-26
SG10201912699RA (en) 2020-02-27
CO2018001621A2 (es) 2018-02-28
IL276292B2 (en) 2024-02-01
RU2018106060A3 (es) 2019-12-13
PE20180573A1 (es) 2018-04-04
DOP2018000008A (es) 2018-05-15
ECSP18012103A (es) 2018-04-30
RU2018106060A (ru) 2019-08-20
IL276292A (en) 2020-09-30
MY186368A (en) 2021-07-16
MA42023B2 (fr) 2022-01-31
AU2021204116A1 (en) 2021-07-15
BR112018001017A2 (pt) 2018-09-18
AU2016297558B2 (en) 2021-03-25
US11274108B2 (en) 2022-03-15
JP6898914B2 (ja) 2021-07-07
AR105392A1 (es) 2017-09-27
ZA201800082B (en) 2018-12-19
IL276292B1 (en) 2023-10-01
MX2021015102A (es) 2022-02-21
EP3325471A1 (en) 2018-05-30

Similar Documents

Publication Publication Date Title
CO2018001621A2 (es) Inhibidores del receptor del factor estimulador de colonias 1 (csf-1r)
CL2018001685A1 (es) Compuestos heterociclicos como inmuno moduladores.
CO2018006662A2 (es) Agonistas del receptor de apelina y métodos de uso
DOP2017000078A (es) Indazoles sustituidos con bencilo como inhibidores de bub1.
CL2017002483A1 (es) Compuestos heterocíclicos como inhibidores de lsd1
CL2016002027A1 (es) Ciclopropilamina como inhibidor de la lsd1
DOP2016000144A (es) Moduladores de tetrahidropiridopirazinas de gpr6
EA202092609A1 (ru) Антитела к cd38 для лечения острого миелолейкоза
CO2018007221A2 (es) Heteroarilhidroxipirimidinonas como agonistas del receptor de apelina (apj)
CL2016002157A1 (es) Anticuerpos anti-cd38 para el tratamiento de leucemia linfoide aguda
EA201890052A1 (ru) Регуляторы nrf2
TR201906366T4 (tr) Polisiklik-karbamoilpiridon bileşiklerinin sentezi.
MX2017008444A (es) Picolinamidas como fungicidas.
EA201890093A1 (ru) Комбинированная терапия гемобластозов антителами к cd38 и ингибиторами сурвивина
EA201691610A1 (ru) Анти-jagged1 антитела и способы применения
EA202091731A1 (ru) Ингибиторы аутотаксина и их применения
UY36070A (es) Triterpenoides con actividad inhibidora de la maduración de hiv
CR20160448A (es) Nuevos derivados de piridina
ECSP16074207A (es) Pirazinas moduladoras de gpr6
CO2018008249A2 (es) Composiciones terapéuticas y métodos para el tratamiento de la hepatitis b
UY35823A (es) Profármacos de antagonista de nmda